Researchers at MIT and Massachusetts General Hospital have developed “Sybil” – an artificial intelligence tool that can predict the risk of a patient developing lung cancer within six years, reports Mallika Marshall for CBS Boston.
MIT researchers have developed a new AI tool called Sybil that could help predict whether a patient will get lung cancer up to six years in advance, reports Pranshu Verma for The Washington Post. “Much of the technology involves analyzing large troves of medical scans, data sets or images, then feeding them into complex artificial intelligence software,” Verma explains. “From there, computers are trained to spot images of tumors or other abnormalities.”
MIT researchers are developing targeted drug delivery through the use of nanoparticles to aid in cancer treatment, reports Simone Migliori for Boston Magazine. “Designed to circulate through the bloodstream, these small but mighty travelers [nanoparticles] can deliver a chemotherapy drug directly to a target cancer cell without disturbing any healthy cells along the way,” writes Migliori. “In doing so, patients may be able to avoid some of the worst side effects of chemotherapy drugs while still effectively treating their cancer.”
Researchers from MIT and Mass General Hospital have developed “a deep learning model named ‘Sybil’ that can be used to predict lung cancer risk, using data from just a single CT scan,” writes Sai Balasubramanian for Forbes. “Sybil is able to predict a patient’s future lung cancer risk to a certain extent of accuracy, using the data from just one LDCT [low-dose computed tomography scan],” writes Balasubramanian.
Jake Becraft PhD ’19 and former postdoctoral associate Tasuku Kitada co-founded Strand Therapeutics, a biotech firm developing mRNA therapies for cancer, reports Ryan Cross for The Boston Globe. They created “a way to activate mRNA in the presence of particular microRNAs – a much more useful application for therapies,” writes Cross.
A study co-authored by researchers from MIT found that a person’s ancestry can impact CRISPR’s ability to edit genomes as intended, “particularly in people of African descent, whose genomes are most likely to differ from those used to steer CRISPR to a specific gene,” reports Jocelyn Kaiser for Science.
Prof. Richard Hynes is one of the winners of this year’s Lasker Award, reports Benjamin Mueller for The New York Times, for his work describing how “cells bind to their surrounding networks of proteins and other molecules — findings that pointed the way toward treatments for a number of diseases.”
Prof. Richard Hynes is one of three honorees for the Albert Lasker Basic Medical Research Award, reports Maddie Burakoff for the AP. Hynes and his fellow awardees “helped launch the field of integrin research, which has since led to new strategies for treating diseases,” writes Burakoff.
Prof. Richard Hynes is one of the three recipients of the 2022 Albert Lasker Basic Medical Research Award for his contributions to the field of integrin research, reports Martin Finucane for The Boston Globe. Hynes and his colleagues “provided a greater understanding of the diseases that can result when integrin function is perturbed.”
Doctoral research specialist Morteza Sarmadi speaks with Emily Henderson from News Medical Life Sciences about his work with Prof. Robert Langer and research scientist Ana Jaklenec in developing microparticles that are able to deliver self-boosting vaccines. “We believe this technique can significantly reduce the need to visit a healthcare provider to receive booster shots, a major challenge in remote areas without sophisticated healthcare resources,” says Sarmadi.
Prof. Andrew Lo speaks with Forbes contributor Russell Flannery about his work using finance to help lower the cost of drug development for cancer treatment and therapies. “I started thinking about how we could use finance pro-actively to lower the cost of drug development, increase success rates, and make it more attractive for investors,” says Lo. “Because that's really what the issue is: you need investors to come into the space to spend their billions of dollars in order to get these drugs developed.”
Forbes contributor Russell Flannery spotlights how Prof. Tyler Jacks has “made a mark in cancer work not only by his research but his ability to bring different organizations together.” Jacks discussed the Biden administration’s “Cancer Moonshot” initiative and noted that: “Having specific goals and an action plan for cancer is important. Having a strategy about how to approach the cancer problem is equally important.”
Scientists at MIT are developing a self-boosting vaccine that can provide multiple doses of a vaccine via a single injection, reports Darko Manevski for Newsweek. The technology “could be particularly useful for administering childhood vaccinations in regions where people do not have regular access to medical care,” writes Manevski.
MIT scientists are developing self-boosting vaccine technology that could allow people to receive all of their vaccine doses in one shot, reports The Economist. This technology “would be a game-changer, not only for future pandemics but also for vaccination programs in remote regions where it is harder to deliver boosters,” The Economist notes.
Wall Street Journal reporter Daniela Hernandez spotlights the work of Media Lab Research Scientist Andreas Mershin in developing sensors that can detect and analyze odors. Mershin “is focusing on medical applications of olfaction technology. Inspired by dogs that have demonstrated an ability to sniff out malignancies in humans, he’s working on an artificial-intelligence odor-detection system to detect prostate cancer.”